<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357978</url>
  </required_header>
  <id_info>
    <org_study_id>InfectionandLiver_AT2016</org_study_id>
    <nct_id>NCT03357978</nct_id>
  </id_info>
  <brief_title>Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia</brief_title>
  <official_title>Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia With and Without Substitution of Immunoglobulin G: a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by
      progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer
      susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised
      by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses
      and specific antibodies against pneumococcus. Aim of the present clinical trial is to
      investigate frequency-, intensity- and duration of the infections as well as changes oft
      immune status, dimension of liver disease and tumor risk in patients with A-T, with and
      without immunoglobulin G substitution therapy. Transient elastography (FibroScan) will be
      performed in order to measure liver stiffness as an indication of fatty liver and liver
      fibrosis. A bioelectrical impedance analysis (BIA) is conducted to investigate the exact body
      composition. Ataxia Score is determined to define neurological problems. Every subject
      receives a diary to compile symptoms of infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ataxia teleangiectasia (A-T) is a rare devastating human recessive disorder characterized by
      progressive cerebellar ataxia, immunodeficiency, chromosomal instability and cancer
      susceptibility. The immunodeficiency is expressed by recurring infections. It's characterised
      by decreased lymphocytes data as well as lack of immunglobulin A, immunglobulin G subclasses
      and specific antibodies against pneumococcus as shown in many trials. Additionally the
      patients suffer from a fatty liver with increased transaminases and have the risk for a
      cirrhosis of the liver and a hepatocellular carcinoma. It's known that the dimension of the
      liver disease affects susceptibility to infection. Nevertheless there are only a few studies
      treating this problem.

      Despite the proof of the immunodeficiency polyvalent immunoglobulins (IgG) are not given
      regularly. Own observations show that in spite of the treatment with immunoglobulins the
      progression of a chronic destructive lung disease with development of bronchiectasis hardly
      can prohibited.

      Up to now it isn't cleared if a substitution therapy with immunoglobulins reduces the
      susceptibility to infection. Therefore the aim oft the present clinical trial ist to explore
      frequency-, intensity, and duration oft the infections as well as changes oft the immune
      status, measure of liver disease and tumor risk in patients with A-T, with and without
      immunoglobulin therapy. The study includes five visits, which are performed in all A-T
      patients. Visit 1, 3, 5 are realized in the context of annual follow ups:

        -  To evaluate weight and length of all subjects

        -  To analyze the exact structure of single body compartments such as the lean mass, the
           water compartment or the fat compartment using bioelectrical impedance analysis

        -  To define the neurological status by ataxia score

        -  To get a detailed immune status, vaccination status and liver values as well as special
           tumor markers in blood

        -  To check the lung function using spirometry

        -  To measure liver stiffness using transient elastography (FibroScan)

        -  To compile any symptoms of infection by diary

        -  To investigate the ataxia status and physical condition by means of the
           Five-Times-Sit-to-Stand Test

      Visit 2 and 4 are additionally conducted as study visits:

        -  To get a detailed immune status in blood

        -  To check the lung function using spirometry
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infections in A-T</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of frequency, severity and intensity of infections in A-T patients with and without immunoglobulin G substitution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver disease</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of the degree of liver disease measured by liver enzymes and structural changes by transient elastography (Fibroscan) in A-T patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer risk</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of tumor markers in A-T patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ataxia Telangiectasia</condition>
  <arm_group>
    <arm_group_label>A-T patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution
bioelectrical impedance Analysis
blood draw
transient elastography (FibroScan)
ataxia score
Five-Times-Sit-to-Stand Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bioelectrical impedance analysis</intervention_name>
    <description>Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body</description>
    <arm_group_label>A-T patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood draw</intervention_name>
    <description>Blood samples are taken from sober patients</description>
    <arm_group_label>A-T patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transient elastography (FibroScan)</intervention_name>
    <description>FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound</description>
    <arm_group_label>A-T patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ataxia score</intervention_name>
    <description>Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb</description>
    <arm_group_label>A-T patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Five-Times-Sit-to-Stand Test</intervention_name>
    <description>The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series</description>
    <arm_group_label>A-T patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aim group: genetically and/or clinically diagnosed A-T

          -  age 2-45 years

          -  written informed consent

        Exclusion Criteria:

          -  age &lt; 2 or &gt; 45 years

          -  other diseases with influence on the immune system (i.e. diabetes mellitus, malignoma,
             dialysis-dependent renal failure)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe-University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Woelke, Dr.</last_name>
    <phone>00496930183063</phone>
    <email>sandra.voss@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Zielen, Prof. Dr.</last_name>
    <phone>00496930183063</phone>
    <email>stefan.zielen@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra WÃ¶lke, Dr.</last_name>
      <phone>004969630183063</phone>
      <email>sandra.voss@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Zielen, Prof. Dr.</last_name>
      <phone>004969630183063</phone>
      <email>stefan.zielen@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Zielen</investigator_full_name>
    <investigator_title>Prof. Dr. med. Stefan Zielen</investigator_title>
  </responsible_party>
  <keyword>immunodeficiency</keyword>
  <keyword>liver disease</keyword>
  <keyword>cancer risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

